Learning from large cardiovascular clinical trials: Classical cardiovascular risk factors

Diabetes Research and Clinical Practice

Volumn 68, Issue SUPPL. 1, 2005, Pages

  Kempler, Peter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cardiovascular risk; Diabetes mellitus; Hyperlipidaemia; Hypertension; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PLACEBO; SIMVASTATIN;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DYSLIPIDEMIA; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK REDUCTION; SMOKING HABIT;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; RISK FACTORS; SMOKING;

EID: 20444407302     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.005     Document Type: Conference Paper

References (20)

1. J. Bjornholt, E. Aaser, L. Sandvik, S. Nitter-Hauge, G. Erikssen, and J. Erikssen Fasting blood glucose level predicts cardiovascular mortality in men. Results from 22 years follow-up Eur Heart J 38 Suppl. 1 1996
2. B. Balkau, P. Ducimetiere, S. Bertrais, and E. Eschwege Is there a glycemic threshold for mortality risk Diabetes Care 22 1999 696 699
3. H.C. Gerstein Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 22 1999 659 660
4. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth For the Multiple Risk Factor Intervention Trial research group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
5. M. Laakso, and S. Lehto Epidemiology of macrovascular disease in diabetes Diabetes Rev. 5 1997 294 315
6. UK Prospective Diabetes Study Group Tight blood pressure (BP) control and risk of macrovascular complications in Type 2 diabetes: UKPDS, 38 BMJ 317 1998 703 711
7. L. Hansson, A. Zanchetti, and S.G. Carruters For the HOT study group. Effect of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
8. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, and A. Niklason For the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
9. L. Niskanen, T. Hedner, L. Hansson, J. Lanke, and A. Niklason For the CAPPP study group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an angiotensin-converting-enzyme (ACE) inhibitor compared with a diuretic/β-blocker-based treatment regimen Diabetes Care 24 2001 2091 2096
10. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and U. de Faire For the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
11. L.H. Lindholm, H. Ibsen, B. Dahlöf, R.B. Devereux, G. Beevers, and U. de Faire For the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LiFE): a randomised trial against atenolol Lancet 359 2002 1004 1010
12. L.H. Lindholm, B. Dahlöf, J.M. Edelman, H. Ibsen, K. Borch-Johnen, and M.H. Olsen For the LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study Lancet 362 2003 619 620
13. E.A. Denver, R.G. Woolfson, M. Barnard, and K.A. Earle Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with Type 2 diabetes Diabetes Care 26 2003 2256 2260
14. K. Pyöralä, T.R. Pedersen, J. Kjekshus, and O. Faergeman The Scandinavian Simvastatin Survival Study Group Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease (CHD) a subgroup analysis of the Scandinavian Simvastatin Survival Study Diabetes Care 20 1997 614 620
15. S.M. Haffner The Scandinavian Simvastatin Survival Study subgroup analysis of the diabetic subjects: implications for the prevention of coronary heart disease (CHD) Diabetes Care 20 1997 469 471
16. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
17. The DAIS Investigators Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
18. W.K. Al-Delaimy, W.C. Willett, J.E. Manson, F. Speizer, and F.B. Hu Smoking and mortality among women with Type 2 diabetes Diabetes Care 24 2001 2043 2048
19. S. Yusuf Two decades of progress in preventing vascular disease Lancet 360 2002 2 3
20. P. Gaede, P. Vedel, N. Larsen, G.V.H. Jensen, H.H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes N. Engl. J. Med. 348 2003 383 393